Search results
Showing 8086 to 8100 of 8899 results
Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer (TA447)
This guidance has been updated and replaced by NICE technology appraisal guidance 531.
This guidance has been updated and replaced by NICE technology appraisal guidance 91.
This guidance has been updated and replaced by NICE guideline NG107
Nivolumab for previously treated squamous non-small-cell lung cancer (TA483)
This technology appraisal guidance has been updated and replaced by NICE technology appraisal guidance 655.
Nivolumab for previously treated non-squamous non-small-cell lung cancer (TA484)
This guidance has been updated and replaced by NICE technology appraisal guidance 713.
Venetoclax for treating chronic lymphocytic leukaemia (TA487)
This guidance has been updated and replaced by NICE technology appraisal guidance 796.
This guidance has been updated and replaced by NICE guideline CG82.
Mepolizumab for treating severe refractory eosinophilic asthma (TA431)
This technology appraisal guidance has been updated and replaced by NICE technology appraisal guidance 671.
This guidance has been updated and replaced by NICE technology appraisal guidance 736.
Obinutuzumab with bendamustine for treating follicular lymphoma refractory to rituximab (TA472)
This guidance has been updated and replaced by NICE technology appraisal guidance 629.
This guideline has been updated and replaced by NICE guideline CG137.
This guidance has been withdrawn.
Clopidogrel in the treatment of non-ST-segment-elevation acute coronary syndrome (TA80)
This guidance has been replaced by recommendations 1.3.4 to 1.3.8 in NICE guideline CG94 and by recommendation 1.3.18 in NICE guideline CG172.
Selpercatinib for treating advanced thyroid cancer with RET alterations (TA742)
This guidance has been updated and replaced by NICE technology appraisal guidance 1038.
Crizanlizumab for preventing sickle cell crises in sickle cell disease (TA743)
NICE has withdrawn this guidance. Novartis will stop marketing crizanlizumab (Adakveo) because its marketing authorisation has been withdrawn by the Medicines and Healthcare products Regulatory Agency (MHRA). Novartis has issued a direct letter to healthcare professionals specialising in haematology. No new people will start taking crizanlizumab in the UK. Healthcare professionals should discuss alternative treatment options with people currently having crizanlizumab.